Phase I Study of Milatuzumab for Graft Versus Host Disease

Summary

This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.

Timeline

Start

2013-12

Primary completion

2015-03

Completion

2015-03

Outcome

Outcome not reported

Stopped (Enrollment): “PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled”

Drugs

Indications